Mode
Text Size
Log in / Sign up

Obstetric CVST: 8.28% maternal mortality acutely, 3.17% recurrence in follow-up cohortsAnticoagulants show mixed results for pregnant women with blood clots

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize distinct risks in acute versus prior obstetric CVST; anticoagulation data are heterogeneous.

This meta-analysis examined obstetric cerebral venous sinus thrombosis (CVST) and central venous thrombosis (CVT), distinguishing two clinical populations: women presenting with acute CVST during pregnancy or postpartum, and women with known prior CVST followed through subsequent pregnancies. The authors pooled data on deliveries or livebirths, spontaneous miscarriage, recurrence, maternal mortality, and acute-phase anticoagulation use.

In follow-up cohorts of women with known prior CVST, 69.6% achieved delivery or livebirth (95% CI 59.2 to 78.4%), spontaneous miscarriage occurred in 19.4% (95% CI 13.8 to 26.5%), and CVST recurrence was 3.17% (95% CI 1.43 to 6.89%). Follow-up extended to at least 5 years in these cohorts.

In acute obstetric CVST cohorts, maternal mortality was 8.28% (95% CI 5.65 to 11.97%) and acute-phase anticoagulation use was 92.9% (95% CI 64.8 to 98.9%). The authors note high heterogeneity (I2 = 81.2%) for acute-phase anticoagulation use, which limits confidence in that pooled estimate. Sample size, setting, comparator, and primary outcome were not reported.

The authors emphasize that the two populations should not be conflated: acute CVST carries a substantial mortality burden, whereas women with prior CVST who receive structured risk stratification and follow-up show favorable pregnancy outcomes and low recurrence. Safety data, including adverse events and discontinuations, were not reported. These findings are observational in nature and do not establish causality.

How this fits prior evidence

This meta-analysis extends prior coverage of anticoagulation in thrombotic disease by focusing specifically on obstetric CVST, a population not addressed in earlier reports. Prior coverage showed that adding antiplatelet therapy to anticoagulation did not reduce stroke risk but increased major bleeding, supporting anticoagulation monotherapy. Other prior items addressed anticoagulation in left ventricular systolic dysfunction and stable coronary artery disease, where bleeding and thrombotic tradeoffs were central. This analysis adds pregnancy-specific outcome estimates, including a 3.17% recurrence rate in women with prior CVST, but does not compare anticoagulation strategies directly.

Managing blood clots during pregnancy is a high-stakes challenge for doctors and families. When a mother develops a blood clot in the brain or major veins, the stakes involve both her immediate safety and the health of her baby. This analysis looked at two different groups of women: those facing a sudden, acute clot during pregnancy and those with a known history of clots who were being followed over several years.

For the women with a known history of clots, the results were encouraging. These women had a 69.6% rate of successful deliveries and a low 3.17% rate of the clot returning. However, the data for women facing a sudden, acute clot during pregnancy showed a much more serious situation, with a maternal mortality rate of 8.28%.

It is important to note that these two groups of women are very different. While the long-term follow-up group showed positive outcomes, the acute group faced much higher risks. Because the data for current treatment use was varied across different studies, the results are not perfectly uniform. Talk to your doctor to understand how these specific risks apply to your unique medical history.

What this means for you:
Women with a known history of blood clots may have better delivery outcomes than those with sudden, acute clots.

Common questions

What are the risks for women with a sudden blood clot during pregnancy?

For women facing a sudden, acute blood clot during pregnancy, the data shows a maternal mortality rate of 8.28%. This highlights the serious nature of acute cases compared to other groups.

What are the outcomes for women with a known history of blood clots?

Women with a known history of blood clots showed a 69.6% rate of successful deliveries and a low 3.17% rate of the clot returning during a follow-up period of at least five years.

How common is miscarriage for women with a history of blood clots?

In the group of women with a known history of blood clots, the rate of spontaneous miscarriage was reported at 19.4%.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundCerebral venous sinus thrombosis is a rare cerebrovascular disease of importance both during pregnancy and in the puerperium. However, the existing cohort literature relates to two distinct clinical populations: women with acute onset of pregnancy−/puerperium-associated cerebral venous thrombosis (CVST), and women with known previous CVST who were assessed in connection with a subsequent pregnancy. As these populations address distinct clinical questions and have distinct denominators and follow-up structures, this review has distinguished outcomes from the two populations and synthesized them separately.MethodsA PRISMA-compliant systematic review was conducted searching six bibliographic databases for evidence on CVST/central venous thrombosis (CVT), pregnancy/puerperium, and follow-up cohorts. Cohort studies only have been eligible for inclusion, with the additional criterion of a follow-up period of ≥5 years or participant-level follow-up period of ≥5 years. This particular criterion was used mainly as an aid to interpreting data on recurrence or subsequent pregnancy, while for outcomes related to acute obstetric CVST, it was used simply as a measure of study period. Outcomes have been summarized as pooled proportions by random-effects meta-analysis with pre-specified stratification in follow-up cohorts (women with known CVST in the past) and study period cohorts (acute obstetric CVST).ResultsTwelve studies were included. In follow-up cohorts assessing subsequent pregnancy following previous CVST, deliveries/livebirths pooled to 69.6% (95% CI 59.2 to 78.4%, I2 = 51.7%), spontaneous miscarriage pooled to 19.4% (95% CI 13.8 to 26.5%, I2 = 20.6%), and recurrence of cerebral venous sinus thrombosis during subsequent pregnancy/puerperium pooled to 3.17% (95% CI 1.43 to 6.89%, I2 = 0%). In acute pregnancy/puerperium cerebral venous sinus thrombosis cohorts, maternal mortality pooled to 8.28% (95% CI 5.65 to 11.97%, I2 = 0%), while acute-phase anticoagulation use pooled to 92.9% (95% CI 64.8 to 98.9%) with high heterogeneity (I2 = 81.2%). These outcomes were thus interpreted within the context of their particular population and observation period.ConclusionLong-term follow-up cohorts indicated that subsequent pregnancy following previous cerebral venous sinus thrombosis was associated with good delivery outcomes and low recurrence in cases when CVST management included structured risk stratification and appropriate prophylaxis. Acute obstetric CVST cohorts, on the other hand, dealt with acute morbidity, mortality, and treatment, and not with future pregnancy safety, with significant maternal mortality burden.Systematic review registrationPROSPERO registration number CRD420261328921.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.